Artivion, Inc.
AORTHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. With a market capitalization of $1.25B, it sits in small-cap territory. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
Market Cap
$1.25B
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
32.71
EPS (TTM)
$-0.06
EPS (Fwd)
$0.78
ROE
-0.7%
ROA
2.6%
Cash
$77.3M
Total Debt
$408.0M
Free CF
$13.1M
52W Change
-39.8%
Annual Financials
Cash vs Debt
Where AORT stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, AORT finished 13.31% below its 150-day moving average ($31.02) and 22.31% below its 200-day moving average ($34.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AORT overbought or oversold?
At the August 25, 2026 close, AORT's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AORT has $77.3M in cash with $408.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $13.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -0.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $313.8M (2022) to $441.3M (2025), reflecting a 41% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AORT.